Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients

Naito, Sei; Yamamoto, Naoki; Takayama, Tatsuya; Muramoto, Masatoshi; Shinohara, Nobuo; Nishiyama, Kenryu; Takahashi, Atsushi; Maruyama, Ryo; Sakaguchi, Takashi; Hoshi, Senji; Nagao, Kazuhiro; Yamamoto, Shingo; Sugimura, Issei; Uemura, Hirotsugu; Koga, Shigehiko; Takahashi, Masayuki; Ito, Fumio; Ozono, Seiichiro; Terachi, Toshiro; Naito, Seiji; Tomita, Yoshihiko

doi:10.1016/j.eururo.2008.12.026

Cited by 187 publications

(216 citation statements)

References 27 publications

Supporting

Mentioning

208

Contrasting

Order By: Relevance

“…In this study, we observed that the median CSS following LM appearance was 10.6 months. In previous studies, the median CSS following LM was 7.6-12.6 months (2-4), while the 1-year survival was 38.3% (2). Those results are similar to ours.…”

Section: Discussionsupporting

confidence: 82%

“…The rate of LM was reported to be 9.3-18% (2-5). The prognosis of RCC patients with LM is poor and the median overall survival is 7.6-12 months, which is shorter compared to that of patients with metastasis to other sites (2)(3)(4). Patients with metastatic RCC were treated with interferon and/or interleukin-2 during the cytokine era; however, the response rate to cytokine therapy was reportedly only 10-20% (4).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis

Hamada

Ito

Kuroda

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis

Hamada

Ito

Kuroda

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Bone metastases were shown to be associated with severe bone pain, pathological fractures, spinal cord compression and a short survival Cancer Therapy …”

Section: Discussionmentioning

confidence: 99%

Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function

Maita

Yuasa

Tsuchiya

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

We investigated the inhibitory effect of sunitinib, a newly approved multitargeted tyrosine kinase inhibitor, against the progression of renal cell cancer (RCC) bone metastases in vivo. In vitro cell proliferation was determined using the MTS assay. To investigate the inhibitory effects of sunitinib in vivo, we established luciferase-labeled ACHN Luc cells derived from papillary RCC. Mice in which ACHN Luc cells had been transplanted into the left ventricle to establish bone metastases were treated orally with 40 mg/kg/day sunitinib or vehicle control for 3 weeks. Growth of the cancer cells was monitored using an in vivo imaging system. In addition, 16 patients with metastatic RCC were treated with sunitinib, and serum and urine levels of amino-terminal telopeptide (NTx) were measured as markers of bone resorption. Sunitinib did not inhibit the growth of RCC cells in vitro at clinically or experimentally achievable serum levels (100 nM-1 lM). To investigate the inhibitory effect of sunitinib in vivo, we established luciferase-labeled human RCC cells (ACHN Luc ). Sunitinib prevented the growth of ACHN Luc RCC cells in the bone metastatic mouse model. The number of osteoclasts in sunitinib-treated mice was significantly less than that in control mice. Serum and urine levels of NTx in patients with metastatic RCC declined significantly during the first 4 weeks of sunitinib treatment (p 5 0.027). Sunitinib is a potent anticancer agent for RCC bone metastases, at least for papillary RCC.Bone is a common site of metastasis, with the frequency of solitary or multiple metastases to bone ranging from 24 to 51% in patients with metastatic renal cell cancer (RCC). 1-3 Although bone metastasis is not an independent prognostic factor associated with poor survival, the prognosis of patients with bone metastasis is not favorable when they are treated with cytokines, with an average life expectancy of 8-16 months. [2][3][4] Moreover, bone metastases are associated with poor performance status due to intractable pain and pathological fractures. 5 Because treatment options for RCC patients with bone metastasis are limited, appropriate treatment strategies are desired.Sunitinib is a newly approved, multitarget, small-molecule tyrosine kinase inhibitor for the treatment of metastatic RCC. It inhibits various receptor tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3; stem cell factor receptor (KIT) and PDGF receptors a and b. 6-8 Moreover, sunitinib has been known to inhibit the phosphorylation of colony-stimulating factor (CSF)-1R, resulting in the prevention of osteoclast function and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. 9,10 These findings led us to propose the hypothesis that sunitinib may inhibit tumor growth and osteolysis in bone metastatic lesions in RCC patients.Although establishing a treatment strategy for bone metastases from RCC is important for urologists, the assessment of inhibitory effects on the growth of bone metastases is oft...

show abstract

“…However, the benefi ts of local therapeutic options for metastases from renal cell carcinoma are controversial. Despite retrospective data suggesting consistently that complete resection of solitary or oligometastatic metastatic renal cell carcinoma suggests a favourable prognosis independent of race or geographical location, 9 uncertainty exists as to whether this is because of favourable tumour biology, the role of metastasectomy, or both. Less disputed benefi ts of complete resection include symptom palliation, and delay or withdrawal of systemic treatment, thereby avoiding associated toxicities.…”

Section: Introductionmentioning

confidence: 99%

Local treatments for metastases of renal cell carcinoma: a systematic review

Dabestani

Marconi

Hofmann

et al. 2014

The Lancet Oncology

283

205

View full text Add to dashboard Cite

Local treatment of metastases such as metastasectomy or radiotherapy remains controversial in the treatment of metastatic renal cell carcinoma. To investigate the benefi ts and harms of various local treatments, we did a systematic review of all types of comparative studies on local treatment of metastases from renal cell carcinoma in any organ. Interventions included metastasectomy, radiotherapy modalities, and no local treatment. The results suggest that patients treated with complete metastasectomy have better survival and symptom control (including pain relief in bone metastases) than those treated with either incomplete or no metastasectomy. Nevertheless, the available evidence was marred by high risks of bias and confounding across all studies. Although the fi ndings presented here should be interpreted with caution, they and the identifi ed gaps in knowledge should provide guidance for clinicians and researchers, and directions for further research.

show abstract

Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients

Cited by 187 publications

References 27 publications

Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis

Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis

Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function

Local treatments for metastases of renal cell carcinoma: a systematic review

Contact Info

Product

Resources

About